Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone

This article was originally published in The Gray Sheet

Executive Summary

The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says
Advertisement

Related Content

Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says
Replacing Test Subjects With Computer Models Will Take Cooperation
Adult Data To Support Pediatric Use? FDA Drafts Decision Tree To Assess Potential
Collecting Foreign Data? Come Talk To Us, FDA Says
PMA Panel Asks TherOx For New Data On Cath-Lab-Based Oxygen Therapy
FDA Approves J&J’s Navistar ThermoCool For Atrial Fibrillation Ablation
FDA Panel Success Puts ThermoCool First In Line For AF Ablation Indication
Device Center Enthusiastic About Bayesian Trial Submissions
CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required
CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required

Topics

Advertisement
UsernamePublicRestriction

Register

MT028517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel